Learn More
BACKGROUND SB2, an infliximab (IFX) biosimilar to the reference infliximab (R.I.) product (Remicade), received approval in the European Union for all IFX indications. Many decision algorithms based(More)
BACKGROUND SB2, an infliximab (IFX) biosimilar to the reference infliximab (R.I.) product (Remicade), received approval in EU for all IFX indications. Many decision algorithms based on the(More)
  • 1